Date: September 30, 2015          Administrative Circular:  2015:16

ATTN: Medical Health Officers and Branch Offices
      Public Health Nursing Administrators and Assistant Administrators
      Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
    Chapter 2 - Immunization Program,
    Section IIB – Contraindications and Precautions for Immunization & Section VII – Biological Products

Section IIB – Contraindications and Precautions for Immunization

Entire section updated. Key revisions include:

- Content related to anaphylactic reaction to eggs updated
- Table “Vaccines Containing Latex” updated
- Content added regarding concurrent receipt of antivirals and vaccines
- Content added regarding convalescence from varicella infection and deferral of live vaccine for 4 weeks
- Content changed regarding severe acute illness and possible deferral of immunization

Please remove the entire contents of Section IIB, including the Table of Contents, with pages dated between January 2009 & April 2010
Please insert the revised Section IIB, including the Table of Contents, dated September 2015

Section VII – Biological Products

Influenza Vaccine Intended Use Table

The table has been updated to include FLULAVAL® TETRA which is being added to the available publicly funded influenza vaccines for the 2015/16 season.

Please remove page number: 31b dated August 2015
Please add new page number: 31b dated September 2015
Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV) (FLUZONE® QUADRIVALENT)

Footnote updated to clarify the intended use of this product.

Please remove page number: 32 dated August 2015
Please add new page number: 32 dated September 2015

Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV) (FLULAVAL® TETRA)

A product page has been created for FLULAVAL® TETRA which is being added to the available publicly funded influenza vaccines for the 2015/16 season.

Please add new page number: 32c dated September 2015

Tetanus-Diphtheria (Td) Adsorbed

Page reformatted to be consistent with other tetanus-containing vaccine product pages. Minor revisions were made to ADVERSE EVENTS and PRODUCT COMPONENTS.

Please remove page numbers: 62 & 63 dated April 2010 and January 2010
Please add new page numbers: 62 & 63 dated September 2015

Tetanus-Diphtheria-Inactivated Poliomyelitis Adsorbed (Td/IPV)

As Td/IPV is no longer the product of choice for immunization of adult HSCT recipients - this indication has been removed. Page reformatted to be consistent with other tetanus-containing vaccine product pages, and minor revisions were made to ADVERSE EVENTS and PRODUCT COMPONENTS.

Please remove page number: 66 dated June 2009
Please add new page number: 66 dated September 2015

Tetanus Immune Globulin (Tlg)

Content added to DOSES AND SCHEDULES related to outer timeframe for offering Tlg.

Please remove page number: 67 dated April 2015
Please add new page number: 67 dated September 2015
Please also remove the Table of Contents for Section VII – Biologicals Products dated August 2015 and replace with the enclosed updated Table of Contents dated September 2015.

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at christine.halpert@bccdc.ca

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:

Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Craig Thompson
Director of Immunization
Healthy Populations and Development Branch

Warren O'Briain
Executive Director
Healthy Populations and Development Branch